Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4681138 | 0.99 | FAAH (0.38) | FAAHTPSAB1TPSD1TPSG1TAAR1 | |
| SCHEMBL4678512 | 0.89 | MGLL (0.41) | FAAHMGLL | |
| SCHEMBL4684682 | 0.87 | MGLL (0.50) | MGLL | |
| SCHEMBL4681022 | 0.86 | TPSAB1 (0.39) | FAAHTPSAB1TPSD1TPSG1KDM1A | |
| Hydrochloric Acid SCHEMBL4679268 | 0.86 | MGLL (0.49) | MGLL | |
| Hydrochloric Acid SCHEMBL4681632 | 0.85 | TPSAB1 (0.38) | FAAHTPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL5881504 | 0.83 | ITGB1 (0.39) | FAAHTPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL905850 | 0.83 | NPC1 (0.47) | FAAHNPC1RAB9AMGLL | |
| Hydrochloric Acid SCHEMBL4681418 | 0.83 | ITGB1 (0.39) | FAAHTPSAB1TPSD1TPSG1KDM1A | |
| Hydrochloric Acid SCHEMBL4677737 | 0.83 | NPC1 (0.46) | FAAHNPC1RAB9AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | FAAH 1290/4885TPSAB1 949/4885TPSD1 836/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | FAAH 1290/4885TPSAB1 949/4885TPSD1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.